unknown by unknown
analysis of tumour tissue demonstrated that selective virus replication had 
occurred.   
In the trial reported here, patients with high grade glioma had their tumours 
surgically resected and 10
5 pfu of the HSV1716 injected into tissue adjacent 
to the cavity. This allowed assessment of safety HSV1716 injection into 
normal brain. Of the twelve patients recruited, seven had recurrent disease, 
and five were newly diagnosed. Eleven patients received further treatment, 
either radiotherapy or chemotherapy. No evidence of toxicity associated with 
HSV1716 has been detected one patient who became ill with pyrexia of 
unknown origin (six weeks following HSV1716) but with no evidence of 
systemic herpes simplex infection, clinically or immunologically was given 
intravenous Acyclovir as a precautionary measure. 
Two of the patients with recurrent glioblastoma have died due to disease 
progression at two and six months post virus injection, and four of the 
remaining ten patients have shown clinical and radiological evidence of 
tumour regrowth. One of the newly diagnosed patients who showed evidence 
of tumour regrowth has undergone further surgical resection. The remaining 
six patients are presently well at 7 weeks to 9 months post virus 
administration. 
This study has shown HSV1716 into tumour cavity to be a safe approach. 
Subsequent time to progression data will provide evidence of potential 
efficacy. The information obtained from this and previous studies allows 
informed design of planned Phase 2 efficacy trials. 
6.6
EVALUATION OF DRUG COMBINATIONS AS A STRATEGY TO 
ERADICATE QUIESCENT LEUKAEMIC STEM CELLS IN 
CHRONIC MYELOID LEUKAEMIA  
H. Jłrgensen*, E. Allan, S. Graham, L. Richmond, J. Godden and T. 
Holyoake 
ATMU, Dept of Medicine, University of Glasgow, Royal Infirmary, Glasgow 
G31 2ER.
The development of a small molecule antagonist of BCRABL, the fusion 
oncoprotein that is thought to be causative in Chronic Myeloid Leukaemia 
(CML), heralds a new era in the treatment of this otherwise refractory 
disease. However, possible mechanisms of resistance to Glivec
ﬁ (imatinib 
mesylate, Novartis, Switzerland) have been described including gene 
amplification and P-glycoprotein up-regulation.  We have previously 
demonstrated the existence of quiescent (G0), leukaemic (Philadelphia, Ph
+), 
stem (CD34
+) cells in all CML samples studied.  Moreover, these cells have 
been shown to be insensitive to Glivec
ﬁ in vitro, even at a concentration 10-
fold higher than normally achieved in patient plasma (Graham et al., Blood 
2002; 99(1): 335). Indeed, in the presence of growth factors, the percentage 
recovery of input CD34
+ cells in the G0 fraction was significantly greater in 
the presence of Glivec
ﬁ than in the absence of drug, suggesting an 
accumulation of G0 cells, an effect modulated by the drug itself. Further, Ph
+
CD34
+ G0 cells have been identified by D-FISH in the majority of patients in 
complete cytogenetic remission following Glivec
ﬁ treatment who mobilised 
sufficient CD34
+ cells for peripheral blood stem cell harvest.  We believe it is 
imperative to formulate a strategy to eradicate the persistent Glivec
ﬁ-
insensitive G0 stem cell population that retains the theoretical ability to 
repopulate the disease.  
Standard 
3H-thymidine-uptake cell proliferation assays have been performed 
using the human Ph
+blast crisis derived cell line, K562, in order to determine 
the effective concentration range of individual drugs selected to be tested for 
additive/synergistic activity in combination with Glivec
ﬁ.  Currently, two 
drugs have been assayed, namely the anti-metabolite cytosine arabinoside 
(Ara-C), and the novel farnesyltransferase inhibitor (FTI) SCH66336 
[Schering Plough].  Both Ara-C and FTI were effective inhibitors of K562 
proliferation (IC50s of 0.05￿M and 10￿M, respectively). Encouragingly, 
when tested in combination at their individual IC50, Ara-C plus Glivec
ﬁ
(IC50 = 0.5￿M) elicited >92% inhibition with respect to no drug control, FTI 
plus Glivec
ﬁ produced >94% inhibition of K562 proliferation.  In order to 
determine the effect, if any, of these combinations on the Ph
+ CD34
+ G0 cell 
population, methodology developed in our lab, using the vital fluorescent 
dye, CFSE, to track cell divisions, was implemented.  Briefly, Ph
+ CD34
+
primary CML stem cells are labeled with CFSE and cultured for 72 hours ±
test compound(s) in the presence of 5 growth factors.  The cells remaining 
viable (PI
-) are then sorted on the basis of CFSE fluorescence intensity and 
the percentage recovery of input cells can then be calculated for all peaks 
(undivided and divided). Interestingly, both Ara-C and FTI individually 
caused an apparently greater accumulation of G0 cells than Glivec
ﬁ alone. 
Moreover, Ara-C in combination with Glivec
ﬁ elicited a further 38% increase 
in number of viable, leukaemic stem cells than with Ara-C alone.  Further 
experimental compounds will be tested in this system, namely LY294002 
(CN Biosciences), PEG-Intron (Schering) 17 AAG and Byrostatin (both NCI, 
Bethseda. MD). 
6.7
COMPARISONS OF PROGNOSTIC FACTORS IN PATIENTS 
PARTICIPATING IN PHASE I CLINICAL TRIALS WITH 
CONVENTIONAL CYTOTOXIC DRUGS VERSUS NEW NON-
CYTOTOXIC AGENTS 
C Han*, J Braybrooke, DT Mackintosh, TS Ganesan, AL Harris, DC Talbot  
Cancer Research UK, University of Oxford, Churchill Hospital, Oxford, OX3 
7LJ, UK. 
Aims: Little is known about prognosis of patients entering phase I trials. The 
objectives of this retrospective study were: (1) to identify prognostic 
variables for toxicity and survival in patients (pts) participating in phase I 
clinical trials a single centre; (2) to compare characteristics of pts treated with 
cytotoxic chemotherapy (CT) and non-cytotoxic drugs (non-CT); (3) to 
determine whether being treated by non-CT might have any impact on 
prognosis or toxicity. 
Patients and methods: Data were collected from 420 (114 CT, 306 non-CT) 
pts enrolled in 16 phase I trials (5 CT and 11 non-CT trials) in our institution 
between 1991 and 2000. Pt characteristics: 210M, 210F, median age 56 yrs 
(22-87), median PS 1 (0-3), median duration of treatment 57 days (2-393). 
The chi-square test and Mann-Whitney test were used to compare treatment 
groups. Univariable analyses of survival times were performed using the log-
rank test.  Cox proportional hazards model was adopted to estimate 
prognostic factors in overall survival (OS). The Prognostic Index (PI) was 
generated from data on all 420 pts.  A logistic regression model was used to 
explore predictive variables of toxicity. All studies were approved by the 
Central Oxford Research Ethics Committee. 
Results: Overall tumour response: 4.5% (95% CI: 2.7-7.0%); Median OS: 
202 days (95% CI: 189-249). Multivariate analysis showed that pts with 
better PS, high Hb, WBC or LDH in normal range and fewer sites of 
metastases had significantly better OS. Males, pts with low platelet count, 
high WBC count or treatment with a non-CT phase I agent had significantly 
less chance of toxicity. Comparing CT with non-CT treated groups: the CT 
group had a higher proportion of females (p < 0.001), were younger (p = 
0.04), had better PS (P=0.02), were more likely to have liver involvement 
(p<0.001) and have LDH in normal range (p=0.001). Pts in the CT group had 
a longer duration of treatment (median time on study 73 vs 51 days, 
p<0.001), better tumour response (1 CR and 15 PR versus 3 PR, p<0.001). 
Median survival was not significantly different between the CT and non-CT 
groups (260 vs 192 days, p = 0.47). In pts with liver metastases (n = 127) 
median survival was significantly shorter in the non-CT group (137 vs 228 
days, p = 0.02).  
Conclusion: Multivariate analysis supports the view that high LDH or WBC, 
low Hb, poor PS and a higher number of metastases are independent adverse 
prognostic variables for survival. Female, treatment with phase I CT drugs, 
low baseline WBC and high platelet counts are independent predictors of 
toxicity. Cytotoxic agents, compared to non-CT, are more likely to induce 
response, although OS is not affected by the class of agent. We conclude that 
entry into a phase I trial of a non-CT drug is a safe option in this population 
of usually heavily pre-treated pts. The PI generated from these data could be 
used to estimate the survival probability for pts entering phase I studies in the 
future. 
6.8
AIM HIGH ￿ ADJUVANT INTERFERON IN MELANOMA (HIGH 
RISK): THE COSTS.  
B.W.Hancock*
1, S.Dixon
2, L.A.Turner
1, K.Wheatley
3, N.Ives
3, M.Gore
4,
1Weston Park Hospital, Sheffield, 
2School of Health & Related Research, 
Sheffield 
3University of Birmingham, 
4Royal Marsden Hospital, London 
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with confirmed transitional cell carcinoma of the bladder received 
pimonidazole prior to transurethral resection of the tumour. Sections 
available from 26 tumours were double stained for pimonidazole (hypoxia) 
with Ki67 (proliferation), & pimonidazole with CD31/34 (vascularity). 
Sections were also stained for GLUT 1 and CA9. Sections were analysed 
with the aid of image analysis software. 
The median hypoxic fraction assessed by pimonidazole was 9% (range 0 to 
38%). The geographical match and fraction of tumour stained by GLUT 1 
and CA9 was very similar to pimonidazole (correlation coefficient 0.86 and 
0.76 respectively). Most staining was distant from vessels (median 99µ m). 
Some hypoxia was close to vessels (<40µ m), suggesting a perfusion limiting 
mechanism to oxygen delivery in these areas. Dual staining for pimonidazole 
and proliferation showed a predominantly inverse relationship between these 
factors. However, some hypoxic regions of less than 40µ m from a vessel had 
a higher proliferative index than those further away from vessels.  
Having confirmed GLUT1 and CA9 as appropriate intrinsic markers for 
hypoxia, archived paraffin embedded samples of bladder carcinoma from 64 
patients treated with ARCON were obtained. Sections were stained for 
GLUT1, CA9, Ki67 and CD31/34 and analysed as above. 
The median age of the group was 72.9 years (range 38 to 88 years). Six 
patients had T1 disease, 19 had T2 disease, 38 had T3 disease and one had T4 
disease. Forty-five tumours were grade 3, 17 were grade 2 and 2 were grade 
1. The median follow up time was 27 months.  
The median stained fraction for GLUT1 was 6.5% (range 0 to 62%) and for 
CA9 was 3.5% (range 0 to 67%). Those patients above the median (more 
hypoxic tumours) for each marker had a statistically significantly worse 
cause specific survival (GLUT1 p<0.005, CA9 p<0.003) but not local 
recurrence or metastasis free survival, analysed with a log rank test. A 
multivariate analysis, accounting for stage, age, grade, Ki67 index and 
vascularity confirmed hypoxic fraction as an independent factor in cause 
specific survival (GLUT1 p<0.02, CA9 p<0.03). 
In conclusion, hypoxia is a significant factor in bladder cancer, and can be 
quantified with both extrinsic and intrinsic markers. Staining patterns are 
consistent with diffusion limited and perfusion. limited mechanisms of 
hypoxia. Proliferation is reduced in hypoxic areas, the greatest effect seen 
with increasing distance from vessels. In a cohort of patients with bladder 
cancer treated with ARCON, hypoxic tumours were associated with a 
significant reduction in cause specific survival. 
7.4
A NOVEL PROMOTER-ENHANCER FOR HYPOXIA-
SELECTIVE GENE THERAPY. 
N Chadderton
1*, RL Cowen
1, KJ Williams
1, PJ Ratcliffe
3, AL Harris
2, IJ 
Stratford
1,
1School of Pharmacy and Pharmaceutical Sciences, University of 
Manchester, Manchester M13 9PL, UK, 
2IMM, John Radcliffe Hospital, 
Oxford OX3 9DU, UK, 
3Welcome Trust Centre for Human Genetics, Oxford 
OX3 7BN, UK. 
We are developing a cancer gene therapy targeted to hypoxia, a unique 
feature of solid tumours, which is transcriptionally silent in normal tissues.  
The efficacy of transcriptional targeting with any specific promoter is directly 
related to the toxicity of the transgene being used.  The development of 
tightly regulated specific enhancer/promoter elements is pivotal to deliver 
potent therapeutic genes to provide a clinically relevant treatment modality. 
Hypoxic response is dependent upon the binding of the transcription factor 
HIF-1 to its cognate receptor, the hypoxia response element (HRE).  Using 
HREs derived from the mouse phosphoglycerate kinase (PGK) and lactate 
dehydrogenase (LDH) genes in combination with minimal promoter elements 
from the tumour associated carbonic anhydrase-9 (CA-9) we have developed 
a number of novel promoter enhancer combinations tightly controlled by 
hypoxia.  
CA-9 is strongly inducible by hypoxia in a broad range of tumour cells, 
yielding levels of expression comparable to those achieved with full length 
SV40.  This response is regulated by a HRE within the minimal promoter.   
The HRE-CA-9 elements were introduced into the pGL3-basic luciferase 
reporter vector and transiently transfected into a panel of 9 human tumour 
cell lines.  The response of the vectors to air or anoxia (0.002% O2) for 16 
and 40 hours was tested.  A range of optimal HRE driven SV40 constructs 
(pGL3-Prom), and CA-9 alone vectors were tested in parallel for comparison.  
We have consistently seen a 6-fold reduction in spurious background 
expression following evaluation of the HRE-CA-9 constructs against their 
HRE-SV40 pairs. We have further enhanced anoxic induction by exploiting 
the unique positioning of the CA-9 HRE, 4bp from the transcriptional start 
site, to construct novel hypoxia regulated enhancer and promoter ￿fusions￿.  
The replacement of the native CA-9 HRE with an optimal HRE composed of 
a triplicate LDH HRE (LDH
3-) resulted in up to a 30-fold enhancement of 
expression compared to the native CA-9.  Whilst maintaining transcriptional 
silence in air we have achieved levels of induction comparable to our 
optimized vector, LDH
3-SV40.  
This application of the minimal CA-9 promoter provides both a further 
degree of hypoxia regulated, tumour-specific expression and an attractive 
alternative to viral promoters that can be shut down in vivo. This data 
demonstrates the ability of this novel vector to deliver a suitably high level of 
gene expression for gene therapy. 
7.5
HYPOXIA SELECTIVE GENE DIRECTED ENZYME PRODRUG 
THERAPY   
Rachel L. Cowen*1, Kaye J. Williams1, Mohammed Jaffar1, Adam V. 
Patterson1,7, Brian A. Telfer1, and Ian J. Stratford1. 
1school of pharmacy and pharmaceutical sciences, university of manchester, 
oxford rd., manchester, u.k., 7auckland cancer society research centre, the 
university of auckland, auckland 1000, N.Z. 
The aim of our research is to combine hypoxia driven gene therapy and 
bioreductive chemotherapy to selectively target therapeutically refractive 
hypoxic tumours. to this end we have developed a novel synthetic series of 
indolequinone pro-drugs similar in structure to the clinical bioreductive drug 
mitomycin c (mmc). upon evaluation of the bioreductive cytotoxicity of this 
series in aerobic and hypoxic conditions a lead compound was identified 5-
aziridinyl-3-hydroxymethyl-1-methylindole-4,7-dione (629). we have 
compared the potency of 629 and its selectivity for activation by the reducing 
enzymes cytochrome P450 reductase (P450R) and dt-diaphorase (DTD) 
using stable cell lines, derived from a panel of human breast carcinoma cell 
lines, which over-express these enzymes. 
IC50 (µ M) Cell line  Clone  Enzyme induction 
Air Anoxia 
HCR
WT -  34.82  0.268  130 
P450R 8  2.526  0.00408 619
MDA468
DTD 115  0.02 0.00446 4.9 
WT -  11.2  0.57  19.6 
P450R 60  0.49  0.0093  52.7 
T47D
DTD 278  0.18 0.025 7.3 
WT -  25.6  2.56  10 
P450R  28  2.15 0.036 59.7 
MDA231
DTD 935  0.0225 0.0133 1.7 
The data above suggests that 629 is preferentially activated through one 
electron reduction under conditions of low oxygen making it an ideal prodrug 
for an hypoxia driven GDEPT approach. To activate this novel pro-drug we 
have constructed adenoviral vectors encoding for constitutive P450R 
expression (Ad CMV P450R) and two vectors encoding for hypoxia induced 
P450R expression. These vectors ad PGK P450R and Ad LDH P450R 
contain hypoxia responsive promoters derived from phosphoglycerate kinase 
and lactate dehydrogenase a, respectively. We have demonstrated that all 
three viruses infect the breast tumour cell lines with high efficiency  (40-80% 
transduction with moi 300). Using ad CMV P450R a 13 to 40 fold over-
expression of P450R can be achieved compared to uninfected cell levels. We 
have also demonstrated a 5-10 fold increase in P450R levels specifically 
restricted to cells infected with Ad PGK P450R and Ad LDH P450R that 
have been exposed to hypoxia. These vectors are currently being evaluated 
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7.6
VIRUS-DIRECTED ENZYME PRODRUG THERAPY (VDEPT): 
CLINICAL TRIALS WITH ADENOVIRAL NITROIMIDAZOLE 
REDUCTASE (Ad-ntr) 
Daniel H Palmer
*, 1, Vivien Mautner
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2, Simon 
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2, Diana Hull
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David J Kerr
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1
1.Cancer Research UK Institute for Cancer Studies, University Of 
Birmingham, UK; 2. Queen Elizabeth Hospital, Birmingham, UK; 3. 
Department Clinical Pharmacology, University of Oxford, UK; 4. COBRA 
Therapeutics Ltd, Keele, UK. 
The bacterial enzyme nitroreductase (ntr) converts the prodrug, CB1954, to a 
highly toxic, short-lived, bifunctional alkylating agent. Since there is no 
human homologue of ntr, a VDEPT approach utilising ntr / CB1954 is 
feasible. 
We have constructed a replication deficient adenovirus (Ad-ntr) that 
expresses ntr from the non-selective CMV promoter. Using Ad-ntr we have 
demonstrated in vitro activity, with a marked bystander effect, in a range of 
tumour cell lines. We have also demonstrated in vivo activity in 
subcutaneous xenograft models following intratumoural injection of Ad-ntr 
followed 48 hours later by intravenous CB1954.
A phase I trial to determine the maximum tolerated dose of Ad-ntr was 
undertaken in patients with hepatic metastatic colorectal cancer awaiting 
hepatic resection. Escalating doses of virus (1.05x10
8 ￿ 1.05x10
11) have been 
administered into the tumour percutaneously under ultrasound guidance. 
Three patients were treated at each dose level and additional patients were 
recruited if there was significant (>grade 2) toxicity. Liver resection was 
performed 48-96 hours after virus injection following which the tumour was 
examined for evidence of ntr expression immunohistochemically. 
11 patients have entered this study (virus particle dose of 10
8, n=3; 10
9, n=3; 
10
10 , n=4; 10
11 , n=1). Toxicity has been minimal (1 patient had systemic flu-
like symptoms) and there is a dose-related increase in PCR aided detection of 
viral DNA in venous blood. Neutralising antibodies to Ad-ntr are formed but 
there is significant inter-patient variation in kinetics and antibody class. Ntr is 
detected in resected tumours (1-3% of cells) with a dose-dependent increase 
in cell positivity. We have not yet reached our target percentage of cancer 
cell population staining positively for ntr, at which stage we will co-
administer CB1954 at a dose ascertained in an earlier phase I and 
pharmacokinetic study (24mg/m
2 IV). 
Ad-ntr has also entered clinical trials of intratumoural injection in head and 
neck and prostate cancer. 
7.7
DIRECT INJECTION OF ADENOVIRUS FOR ENZYME PRODRUG 
THERAPY OF PROSTATE CANCER
J.G. Young
1, H.Y. Leung
3, P.F. Searle
1, V. Mautner
1, A Howie
2, M.Horne
4,
J.Ellis
4, J.Gilbert 
4; D.E. Neal
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4, A.P. Doherty
2, D.M.A. Wallace
2,
N.D. James
1*. (1). CRC Institute for Cancer Studies, University of 
Birmingham (2). University Hospital Birmingham, (3). Freeman Hospital, 
Newcastle upon Tyne, (4). Cobra Therapeutics, Keele. 
Introduction: the ease of direct access to the prostate by transperineal, 
transurethral and transrectal routes makes locally targeted therapies for 
prostate cancer a viable option. We are undertaking a clinical trial of gene 
therapy administered by direct intraprostatic injection of adenovirus followed 
by intravenous injection of prodrug. The transgene e. Coli nitroreductase (ntr) 
has been inserted into a replication deficient adenoviral gene therapy vector, 
called ctl102, under the control of the cytomegalovirus immediate early 
promoter. Ntr converts the weak monofunctional alkylating agent 5-(aziridin-
1-yl)-2,4-4-dinitrobenzamide (cb1954) into a highly cytotoxic bifunctional 
alkylating agent that kills both replicating and non-replicating cells. In 
preclinical models, intratumoural ctl102 injection of subcutaneous pc-3 
tumours in nude mice, followed by systemic cb1954 resulted in inhibition of 
tumour growth. The study involves: (1) a marker study to optimise a clinical 
protocol for in vivo prostatic ntr expression, (2) investigation of the effects of 
direct injection of escalating doses of ctl102, with cb1954, into locally 
recurrent prostate cancer. Patients & methods: virus tropism for the prostate 
was verified by ex vivo infection of thin slices of freshly resected prostate 
tissue with a related virus expressing green fluorescent protein (ad-gfp) in 
place of ntr. The trial is divided into two parts; firstly the marker study 
involves a dose escalation phase i investigation in patients scheduled to 
undergo radical prostatectomy. Secondly, we will investigate a combination 
of virus and prodrug in patients with locally recurrent disease. The patients 
will undergo intraprostatic injection of ctl102 under transrectal ultrasound 
control in escalating doses, starting from 10
10 adenoviral particles, rising to 
10
12 particles, in cohorts of three patients, with subsequent radical 
prostatectomy at 48-72 hours post injection. Ntr expression in the resected 
tissue is assessed by immunohistochemistry. The dose escalation is aimed at 
establishing the dose of ctl102 at which significant transgene expression is 
detected as well as conventional phase i toxicity endpoints. Results: in vitro 
culture of fresh prostate tissue with adenovirus expressing gfp revealed 
diffuse expression of transgene throughout glandular & stromal elements. 2 
patients have now been treated with ctl102 in the marker study with 10
10
particles of adenovirus with no serious adverse reactions.  Trus images 
following injection demonstrate hyperechoic virus suspension disseminating 
slowly throughout the injected prostate lobe. Immunohistochemistry of 
prostate resected from the first patient has revealed transgene expression, 
apparently confined to glandular epithelium. Discussion: direct intraprostatic 
injection appears to be feasible and safe. Early results suggest that injected 
material disseminates via the prostatic ducts, the tissue of origin for prostate 
cancer. Evidence of virus infection and expression of the ntr protein has been 
seen at the lowest dose level and dose escalation is planned. Once nr 
expression at pre-determined levels has been demonstrated, the trial will 
proceed to administration of both virus and prodrug in locally recurrent cases.   
7.8
RADIATION-ACTIVATED PRODRUGS: HYPOXIA-SELECTIVE 
RADIOLYTIC RELEASE OF POTENT 
CHLOROMETHYLBENZINDOLINE (CBI) CYTOTOXINS FROM 
NOVEL NITROARYLMETHYL QUATERNARY (NMQ) PRODRUGS 
Kriste A.G.*, Tercel M., Stribbling S.M., Botting K.J and Wilson W.R., 
Auckland Cancer Society Research Centre, The University of Auckland, 
Private Bag 92019, Auckland, New Zealand. 
Hypoxia is a major negative prognostic factor in radiation therapy. We have 
previously suggested the possibility of activating non-toxic prodrugs to 
potent cytotoxins by reducing them with ionizing radiation in the absence of 
oxygen. Reductive fragmentation of the nitroarylmethyl quaternary (NMQ) 
ammonium prodrugs of mechlorethamine (HN2) has been demonstrated by 
radiation under anoxic conditions, but the prodrugs are not sufficiently stable 
in vivo, and the released nitrogen mustard cytotoxin is not sufficiently potent 
for this mechanism to be therapeutically useful at the radiation doses used 
clinically. The aim of this study was to develop novel NMQ prodrugs capable 
of releasing significantly more potent chloromethylbenzindoline (CBI) 
cytotoxins on radiolytic reduction. Novel 5-amino- or 5-hydroxy-seco-CBI 
cytotoxins were synthesized and demonstrated to have IC50 values (following 
4 hr exposure) of ca.1 nM in a panel of human tumour cell lines. The 
corresponding 4-nitroimidazolyl (4NI) and 2-nitropyrrolyl (2NP) NMQ salts 
were 20 to 200-fold less potent, demonstrating significant deactivation in the 
prodrug form. When cells were exposed under anoxic conditions, IC50 values 
were 1.4 to 8-fold lower, indicating modest bioreductive (enzymatic) 
activation under anoxia. The hydroxy-NMQ-CBI prodrugs had superior 
stability to the amino analogues in culture medium, as assessed by LC/MS, 
and were investigated further. When irradiated in anoxic formate buffer, 
these NMQ-CBI prodrugs (20 ￿M) released their hydroxy-CBI effectors 
efficiently (HPLC analysis; G values 0.45-0.54 ￿mol J
-1), indicating a 
stoichiometry close to one reducing equivalent. The 4NI and 2NP prodrugs (5 
￿M) were irradiated in anoxic human plasma and effector release was 
assessed by bioassay. These experiments demonstrated a 10 to 15-fold 
increase in cytotoxicity at 18 Gy, with an estimated G value for hydroxy-CBI 
release of ca 0.02-0.08 ￿mol J
-1.The extravascular diffusion properties of the 
4NI and 2NP prodrugs are currently being assessed in a multicellular layer 
tumour model, while initial studies in mice indicate that the MTD values for 
the NMQ prodrugs are more than 10-fold higher than for the CBI effector, 
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activity against hypoxic cells in HT29 tumors, in combination with radiation, 
is in progress. 
This work was supported by the Wellcome Trust and the New Economy 
Research Fund of New Zealand. 
8.1
NOVEL DIRECT TARGETS FOR THE CONTROL OF GROWTH BY 
c-MYC  
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The proto-oncogene product c-Myc lies at the interface between cell growth 
and division, impacting directly on both these processes.  Indeed, Myc can 
stimulate cell growth (mass increase) independently of cell cycle effects.   
Since the bulk of a cell’s dry mass is protein, growth is determined by the rate 
at which protein accumulates.  Accordingly, Myc has been shown to 
stimulate the production of the protein synthetic apparatus.  Activation of 
Myc causes increased synthesis of translation factors, ribosomal proteins and 
rRNA (1-3).  We have found that c-Myc also activates the transcription of 
tRNA genes by RNA polymerase (pol) III.  Thus, tRNA transcripts are 
rapidly induced by Myc in primary human fibroblasts.  Furthermore, the 
expression of pol III products is significantly reduced following targetted 
disruption of the c-Myc gene.  These effects reflect the direct action of c-Myc 
on the pol III machinery.  Chromatin immunoprecipitation reveals the 
presence of c-Myc at tRNA genes in vivo.  Moreover, c-Myc binds to the pol 
III-specific transcription factor TFIIIB.  Inducing tRNA production is likely 
to contribute to the activation of protein synthesis that enables Myc to 
stimulate cell growth.  
1. Elend, M. & Eilers, M. (1999). Curr Biol 9, R936. 
2. Schmidt, E.V. (1999).Oncogene 18, 2988.  
3. Grandori, C., Cowley, S.M., James, L.P. & Eisenman, R.N. (2000).  
    Annu Rev Cell Dev Biol 16, 653. 
8.2
DIFFERENTIAL EXPRESSION OF FIBROBLAST GROWTH 
FACTOR RECEPTOR SUBSTRATES  IN HUMAN MALIGNANCIES 
SY Ng*, CN Robson, DE Neal, HY Leung.  Prostate Research Group, School 
of Surgical and Reproductive Sciences, Medical School, University of 
Newcastle, Newcastle upon Tyne, NE2 4HH.
Introduction
FGF receptor substrate (FRS), a membrane-anchored adapter protein targets 
signalling molecules to the plasma membrane in response to FGF stimulation. 
The two FRS isoforms, FRS2α  and FRS2β  (commonly referred to as FRS-2 
and ￿3), are structurally similar and share 49% amino acid sequence identity. 
FRS is required for FGF-induced MAPK activation. We examined the levels 
of FRS-2 and -3 expression in a panel of human cancer cell lines and 
correlated their expression to FGF induced MAPK activation.  
Materials and Methods
FRS-2 and -3 expression was detected by RT-PCR using specific primers. 
The following cell lines were included: prostate (LNCaP, PC3 and DU145), 
breast (MCF7), bladder (T24, J82 and RT112), melanoma(M2), colorectal 
(HT29) and osteoblastic (U2OS).  FRS2 protein expression was further 
quantified  following Western blotting. MCF7, LNCaP and J82 cells were 
selected for MAPK activation study, and the effect of FGF1 on ERK1/2 
activation was quantified using phosphospecific antibody. 
Results
FRS2 transcript was widely expressed and represents the predominant form 
of FRS expressed: 6/8 and 3/8 cell lines with detectable FRS-2 and FRS-3 
expression, respectively.  On Western blotting, LNCaP (prostate) and MCF7 
(breast) cells expressed FRS2 at high level as a 90kD protein. T24 (bladder), 
M2 (melanoma), PC3 and DU145 (both prostate) expressed moderate levels 
of FRS2. FRS2 was expressed at low level in J82 (bladder) and HT29 
(colorectal). The U2OS (osteoblastic) and RT112 (bladder) cells did not have 
any detectable levels of FRS2 expression.  Using densitometry, corrected to 
α -tubulin expression, there was a 16 fold difference in FRS-2 expression 
between MCF7 and J82 cells. Consistent with the observed pattern of FRS2 
expression, FGF1 induced pERK1/2 level was highest in MCF7 cells, 
followed by LNCaP and was lowest in J82; their corresponding ratio of 
activation were 27, 13 and 7, when compared to serum starved controls. Of 
note, the three cell lines (MCF7, LNCaP and J82) did not have significant 
FRS-3 expression. 
Conclusion 
FRS-2 appears to be the predominant form of FRS expressed in human 
malignancies.  FRS-2, in the absence of FRS-3 expression, is adequate for 
FGF induced MAPK activation and the levels of FRS-2 expression correlates 
with the degree of FGF induced MAPK activation. 
8.3
INVESTIGATING THE ROLE OF POLY(ADP-RIBOSE) 
POLYMERASE-1 IN THE RESPONSEOF GLIOMA 
CELLS TO LOW DOSES OF IONISING RADIATION. 
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Introduction:  The terms low-dose hyper-radiosensitivity (HRS) and 
increased radioresistance (IRR) describe the dual phenomena observed in 
many mammalian cell systems where small acute doses of radiation below 
~50 cGy are more lethal per unit dose than higher doses up to ~2 Gy. There is 
evidence that HRS and IRR may reflect dose-dependent changes in DNA 
repair mechanisms. Recent work also suggests that the extent of HRS varies 
according to cell-cycle phase, being most marked in G2. Poly(ADP-ribose) 
polymerase-1 (PARP-1) is an abundant, highly conserved nuclear enzyme 
that rapidly binds to and is activated by DNA single and double strand breaks 
leading to recruitment and modulation of DNA repair processes. Evidence for 
a key role for this enzyme in the cellular response to radiation derives from 
PARP-1 knockout mice, and chemical and molecular inhibitors of PARP-1. 
Inhibition of PARP-1 was associated with sensitisation to radiation doses of 2 
Gy and above (sensitiser enhancement ratio ~1.5) (ref). To date, however, the 
contribution of PARP-1 to the low-dose radiation response has not been 
extensively investigated. We are studying the effect of new, highly potent and 
specific inhibitors of PARP-1 on low-dose clonogenic survival of human 
glioma cell lines that display markedly differing degrees of HRS and IRR, 
with the dual aims of elucidating the role of PARP-1 in these phenomena, 
and investigating the potential for therapeutic symbiosis between PARP-1 
inhibitors and an ultrafractionated radiation schedule. 
Methods:    Clonogenic survival of T98G (HRS+) and U373 (HRS-) human 
glioma cells following low-dose irradiation in the presence of the following 
chemical inhibitors of PARP-1 are being determined using a highly accurate 
fluorescence-activated cell sorting (FACS) clonogenic assay: 3-
aminobenzamide, NU1025, 4-amino naphthalimide (4-ANI) and PJ34. All 
inhibitors have been tested at a range of concentrations to establish the 
optimum dose for modifying radiation response with minimal direct 
cytotoxicity. Further studies will investigate the effect of active drugs on the 
low-dose radiation responses of cells sorted according to cell-cycle phase. 
Results:  Preliminary studies utilising the first generation PARP-1 inhibitor 
3-AB have demonstrated a modification of the low-dose radiation responses 
of both T98G and U373 cell lines that is complicated by the cytotoxic action 
of the chemical. NU1025 has exhibited an unexpected protective effect at low 
radiation doses (characterised by an enhancement in cell plating efficiency) 
that is being investigated. 
Discussion:  Exploiting the potency and specificity of new PARP-1 
inhibitors will elucidate the role of PARP-1 in HRS/IRR, enabling 
assessment of the potential for a therapeutic interaction of such inhibitors 
with an ultrafractionated radiation schedule in the treatment of gliomas.  
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Nuclear BAG-1 expression predicts survival from breast cancer, and 
potentiates oestrogen dependEnt transcription.  
Ramsey I Cutress*, Paul A Townsend, Lynn Wood, Matthew Brimmell, 
Anna Maison, Ron Lee, Mark A Mullee, Peter WM Johnson, Gavin T Royle, 
Adrian C Bateman and Graham Packham.    CRC Wessex Medical Oncology 
Unit, Cancer Sciences Division, School of Medicine, University of 
Southampton, Southampton General Hospital, Southampton, SO16 6YD, 
United Kingdom.  
Background: BAG-1 is a multifunctional protein that binds a wide range of 
cellular targets including heat shock proteins and some nuclear hormone 
receptors. BAG-1 exists as three isoforms, BAG-1L, BAG-1M and BAG-1S.  
BAG-1L contains a nuclear localisation signal which is not present in the 
other isoforms and is predominantly localised in the cell nucleus.  
Aims: To determine if BAG-1 expression is related to clinico-pathological 
features in breast cancer, and to determine if BAG-1 modulates oestrogen 
dependant transcription. 
Methods: Following ethical committee approval (Southampton & S. West 
Hants LREC Submission: 159/00), BAG-1 expression in tumours from 138 
patients with breast cancer treated with hormonal therapy was assessed by 
immunohistochemistry. We performed coimmunoprecipitation assays to 
analyse the interaction of BAG-1 isoforms with oestrogen receptor (ER) 
alpha and beta, and reporter gene assays to measure the effects of BAG-1 
isoforms on oestrogen dependent transcription. 
Findings:  Nuclear but not cytoplasmic BAG-1 immunostaining was 
associated with improved survival in patients treated with hormonal therapy 
(Hazard Ratios: BAG-1 nuclear positive: 0.334 (95% Confidence Interval 
0.138-0.809), BAG-1 nuclear negative: 1; P=0.015). There was also a strong 
inverse association between nuclear BAG-1 expression and tumour grade (χ
2
test for trend=16.51, P<0.001). Nuclear BAG-1 expression was also 
moderately correlated with progesterone receptor (PgR) expression (r = 0.42) 
and ERα  expression (r = 0.31). BAG-1L, but not BAG-1S or BAG-1M, 
interacted with both ERα  and ERβ  and increased oestrogen dependent 
transcription in ER positive MCF-7 breast cancer cells. BAG-1L 
overexpression stimulated transcription through both ERα  and ERβ .
Interpretation: High levels of BAG-1L can increase responsiveness to 
oestrogens in breast cancer cells, and may be important in those cells for 
proliferation and survival.  Similar to PgR and ERα  status, BAG-1 may be a 
marker of responsiveness to hormonal therapy, via its direct effects on 
receptor function. 
8.5
ASSESSMENT OF A PUTATIVE ONCOGENE ZNF217 WITHIN 
AMPLICON 20q BY MULTIPLEX QUANTITATIVE REAL-TIME 
PCR.   
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Detection of gene amplification is a recognised process through which 
oncogenes can be identified.  In this study we have coupled two powerful 
techniques, laser capture-microdissection and multiplex quantitative real-time 
PCR to quickly and accurately assess the gene copy number of candidate 
oncogene ZNF217 in colon cancer.  Several studies of colorectal cancer using 
comparative genomic hybridization (CGH) have identified chromosomal arm 
20q, as the region most commonly gained in this tumour type
1.  In addition 
high density FISH mapping analysis of the 20q amplicon in colorectal cell 
lines within our laboratory has identified ZNF217 to be contained within a 
region, 20q13.2 of high-level amplification.  In this study the frequency and 
level of ZNF217 amplification in 81 colon tumours was assessed by 
multiplex quantitative real-time PCR.  Tumour cells were isolated from 
unfixed 10µ m sections of original snap frozen tumour, using a PixCell II 
laser capture microdissection system (Arcturus Engineering).  Tumor tissue 
was identified and removed by the laser to a microdissection cap.   
Approximately 500 laser pulses were taken per tumor (laser settings spot 
diameter set at 15µ m, pulse duration 5 milliseconds and power 100mW).  
Following protein lysis with 20mg/ml proteinase K, DNA was assessed by 
Taqman PCR using the ABI7700 (PE Applied Biosystems).  Multiplex 
quantitative real-time PCR was used to amplify internal control gene, Beta 
globin and the candidate gene, ZNF217 simultaneously in the same well.  For 
each case, ZNF217 gene copy number was then calculated using the values of 
the mean Ct of ZNF217 (each case was assayed in triplicate) minus the Ct of 
Beta globin.  The tumour values of Ct ZNF217 ￿ Ct Beta globin were 
compared to those of normal diploid colon mucosa (n=10) and colorectal cell 
lines (n=6) for which ZNF217 had been independently established using 
FISH, and assigned a specific copy number.  Of the 81 tumours (42 Dukes￿ B 
and 39 Dukes￿ C) assessed, 18 were diploid, 15 had loss of gene copy and 48 
contained some level of amplification at the ZNF217 locus.  Chi-square 
analysis found no significance in the distribution of ZNF217 gene copy 
number between Dukes￿ B and Dukes￿ C tumours.  In this study we found 
that ZNF217 amplification is a frequent event in colon cancer (48/81 tumours 
= 59.3%) and that the extent of its amplification varies markedly between 
tumours (range 3 - 13 copies). 
1. Rooney PH, Murray GI, Stevenson DAJ, Haites NE, Cassidy J, McLeod 
HL. 1999 Br J Cancer 80:862-873. 
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8.6
GENE EXPRESSION PROFILE ANALYSIS OF TUMOR-DERIVED 
CELL LINES OVEREXPRESSING THE CANDIDATE TUMOR 
SUPPRESSOR GENE,  FIBULIN-1 
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Fibulin-1 is an extracellular matrix protein implicated as a suppressor of 
tumour cell adhesion, motility and growth. The mechanism by which fibulin-
1 mediates these suppressive effects is unclear. Here, we used DNA 
microarray analysis to characterise a profile of genes whose expression is 
modulated by the two predominant fibulin-1 splice variants, fibulin-1C and 
D. The human breast tumour cell line MDA-MB-231 and the human lung 
fibrosarcoma cell line HT1080, both of which express little or no fibulin-1, 
were stably transfected to express fibulin-1C or D variants. Expression of the 
exogenous fibulin-1 variants was confirmed by immunoblot analysis of 
conditioned culture media. Using Affymetrix HuGeneFL arrays containing 
probe sets for 7,129 transcripts, gene expression profiles were determined in 
duplicate for both empty vector and fibulin-1 variant transfectants. 
Comparison of profiles obtained from empty vector- versus fibulin-1D-
transfected MDA-MB-231 cells revealed 58 genes as being differentially 
expressed.  Two hundred and thirty differentially expressed genes were 
identified in comparisons of empty vector- and fibulin-1D-transfected 
HT1080 cells. Furthermore, 28 genes were identified in comparisons of 
empty vector- and fibulin-1C-transfected HT1080 cells. Analysis of these 
profiles revealed evidence of fibulin-1-dependent effects on gene expression 
that included variant-specific effects. For example, expression of 
thrombospondin-1 increased by ~2 fold in fibulin-1D expressing cells (both 
MDA-MB-231 and HT1080), but decreased by 5.0 fold in fibulin-1C 
expressing HT1080 cells. In contrast, collagen alpha 1 type IV expression 
increased > 3.0 fold in cells expressing either fibulin-1 variant. OB-cadherin 
(cadherin 11), a calcium-dependent cell adhesion protein, was differentially 
expressed in fibulin-1 transfectants as compared to empty vector 
transfectants. Specifically, OB-cadherin expression was increased in the 
fibulin-1D-transfected MDA-MB-231 cells (+20.8 fold) and decreased in 
both the fibulin-1C (-9.4 fold) and D (-5.4 fold) transfected HT1080 cells. 
Transcripts for two other genes, ARPC4 (-3.8 fold) and RhoGDIbeta (+2.0 
fold), were differentially expressed between the HT1080 fibulin-1C and 
empty vector transfectants. Based on these findings, it is hypothesised that 
fibulin-1 acts to (a) inhibit ARPC4 gene expression, with a consequent 
negative impact on cell motility, and (b) stimulate Rho GDIbeta gene 
expression, which in turn inactivates Rho-GTPase-dependent pathways, 
resulting in decreased cellular motility and tumourigenic reversion. 
[Supported by the Health Research Board - Ireland, Enterprise Ireland and 
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8.7
THE RELATIONSHIP BETWEEN IN VITRO OXIDATIVE DAMAGE 
FORMATION AND MUTATION AT NUCLEOTIDE RESOLUTION 
IN P53.
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For certain carcinogens the pattern of DNA adducts produced in p53 has been 
shown to be related to the pattern of p53 mutation in associated human 
tumours; establishing causative links between the agents and cancers 
induced. Similarly, a positive correlation between patterns of p53 oxidative 
damage and mutation could help establish the cancer relatedness of oxidative 
DNA damage. Until recently it was not possible to compare induced damage 
with mutation in p53 in vitro, as no suitable mutation assay was available. 
However, in the present study we have compared the distribution of induced 
oxidative damage with the distribution of induced mutation in vitro in human 
p53 using LMPCR and a developed plasmid-based p53 forward mutation 
assay, respectively. Briefly, LMPCR permits the detection of rare DNA 
breaks along single copy genes at nucleotide resolution in the full human 
genome, and combining this technique with damage recognising E. coli Nth 
and Fpg proteins allows for mapping of oxidative base lesions. In the 
mutation assay, a plasmid bearing a full c-DNA copy of human p53 is 
damage-treated  in vitro, then transformed into yeast cells containing an ADE2
gene under the control of a p53 protein-responsive promoter. Transformed 
colonies containing mutant p53 protein are unable to express the ADE2 gene 
and accumulate a red metabolite. The red colonies are picked, grown and the 
human  p53 amplified and sequenced. Using LMPCR we have mapped 
Cu+H2O2-induced oxidative damage along the transcribed strand of exons 5 
and 7 of p53 in isolated human DNA, and have compared this with the 
distribution of mutations induced by Fe+H2O2+ascorbate reactions in the  
plasmid c-DNA p53 exon 5 and 7 sequences. Even with the different gene 
targets and damaging agents used, there is a marked degree of similarity 
between the distribution of damage and mutation, particularly for exon 5 
where the regions of greatest damage (exclusively manifest at guanines in 
codons 142, 149-156, 177-178) strongly correlate with the locations of 
highest mutation frequency (predominately GC/TA transversions and GC/AT 
transitions at codons 143, 151-154, 177). The similarity between the Cu-
dependent damage and Fe-dependent mutation spectra is in line with metal-
ion dependent peroxide-induced damage being more sequence specific than 
metal specific
1. Future studies directly comparing the same gene-targets and 
damaging agents, will allow us to rigorously address which damaged sites are 
critical to mutation, and any correlation with the reported in vivo mutations in 
human tumours will greatly increase relevance of our findings to human 
carcinogenesis. 
1. Rodriguez et. al. (1997) Cancer Research 57, 2394. 
8.8
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BACKGROUND. Tumours arise through an accumulation of genetic and 
epigenetic alterations. In lung cancer, these include deletions on 
chromosomes 3p, 8p, 9p, 5q, Rb, 17p (resulting in loss of heterozygosity, 
LOH) and p53 mutations. This study compared genetic alterations in plasma 
DNA and lymphocyte (control) DNA from patients with lung cancer and 
CRD. METHODS.  5mls blood was collected in sodium citrate, ( full ethical 
written consent was obtained prior to collection). Plasma and cells were 
separated by centrifugation, then stored at -80
0C. DNA was extracted using 
QIAmp Blood DNA Kit (Qiagen). PCR was performed using P
32-labelled 
primer pairs to assess LOH. The products were separated on 6% 
polyacrylamide gel and autoradiographed. RESULTS. 166 patients were 
studied, 53 lung cancer, 113 CRD.  Following initial analysis of 20 markers 
in 32 lung cancer samples, three markers were selected (D3S1300(3p14.2), 
D8S201(8pter-p23), D3S1560(3pter-p24.2)). Patient characteristics and 
results are shown in the table. DISCUSSION. Using a combination of all 3 
markers, an overall detection rate of LOH/MI of 70% is achieved in lung 
cancer patients, and 73% in CRD patients. There is a significant difference in 
the number of genetic lesions between the lung cancer group and CRD group 
(p< 0.001). There is limited data on genetic abnormalities in patients with 
CRD who are at risk of developing lung cancer. A majority of these patients 
were smokers. Results suggest that smokers with chronic lung disease have 
frequent genetic alterations on chromosomes 3 and 8p. 
Table. Patient characteristics and LOH/MI Detection Rates 
Patient Group  CRD  Lung Cancer 
Number 113  53 
Age, median 
(range) 
62  (31-87) 66  (37-82) 
Gender, M/F  78/35  32/21 
Disease  COPD, 32  
Interstitial Lung Disease, 
16
Bronchiectasis, 13 
Occupational, 7 
Asthma, 13  
Others, 32 
NSCLC, 20 
SCLC, 33 
LOH/MI 
Detection: 
Number (%) 
D3S1300  29 (26%)  11 (21%) 
D8S201  24 (21%)  28 (53%) 
D3S1560  67 (59%)  27 (51%) 
Any positive  73%  70% 
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